MedPath

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Phase 2
Recruiting
Conditions
Hairy Cell Leukemia
Interventions
Registration Number
NCT02131753
Lead Sponsor
University of Giessen
Brief Summary

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment.

They have to be untreated so far or may be pretreated with alpha-interferon.

Detailed Description

Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine.

Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the bone marrow.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
210
Inclusion Criteria
  • Patients with histologically verified hairy cell leukemia
  • Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and / or co expression if cell surface antigens cluster of differentiation (CD) 19/CD25 or CD19/CD103 (b-ly7)
  • No previous cytostatic treatment (splenectomy or interferon treatment are allowed)
  • Need for treatment
  • Age at least 18 years old
  • General state of health according to WHO 0-2
  • Current histology, not older than 6 months
  • Written consent by patient
Exclusion Criteria
  • Patients not fulfilling inclusion criteria above
  • Hairy cell leukemia variants (HCL-V): presence of lymphoid cells in bone marrow and / or peripheral blood, which have an intermediate morphology between hairy cells and prolymphocytes (negative TRAP staining and co- expression of CD19/CD103 without CD25
  • Pretreatment with purine analogues or other chemotherapeutics
  • Concomitant corticosteroid therapy
  • Severe dysfunction of the heart (NYHA III or IV), the lung (WHO-Grade III or IV), the liver, except due to lymphoma (bilirubin > 2 mg/dl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase > 2 x upper limit of normal), the kidneys (creatinin > 2 mg/dl or creatinine clearance < 50 ml/min), central nervous system diseases including psychoses.
  • Proven HIV infection
  • Active Hepatitis
  • Other florid infections
  • Anamnesis / diagnosis of other malignant disease (other than non-melanoma associated skin tumours or stage 0 in situ carcinoma of the cervix)
  • Pregnant or lactating women

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cladribine s.c. injection, HCL treatmentCladribine s.c. injection, HCL treatmentCladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
Primary Outcome Measures
NameTimeMethod
Determination of the rate of complete remissions after one cycle with subcutaneous cladribine4 months after treatment
Secondary Outcome Measures
NameTimeMethod
Rate of complete remissions in patient who still have detectable residual disease4 months after treatment

A second cycle of cladribine after an interval of 4 months following the first cycle.

Trial Locations

Locations (28)

Rhön-Saale-Klinik gGmbH

🇩🇪

Bad Neustadt An Der Saale, Germany

Klinik Duisburg-West

🇩🇪

Duisburg, Germany

Krankenhaus Nordwest

🇩🇪

Frankfurt, Germany

University Clinic | Medicinal Clinic IV

🇩🇪

Gießen, Germany

Städtisches Klinikum

🇩🇪

Karlsruhe, Germany

St. Marienkrankenhaus

🇩🇪

Ludwigshafen, Germany

St. Martinus-Hospital

🇩🇪

Olpe, Germany

St. Josefs-Krankenhaus

🇩🇪

Potsdam, Germany

University Clinic Ulm

🇩🇪

Ulm, Germany

Dr. Horst-Schmidt-Kliniken

🇩🇪

Wiesbaden, Germany

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

Community based hemato-oncology medical office

🇩🇪

Wolfsburg, Germany

Universitätsklinik Düsseldorf

🇩🇪

Düsseldorf, Germany

Evangelisches Krankenhaus

🇩🇪

Hamm, Germany

Marienkrankenhaus

🇩🇪

Herne, Germany

St.-Marien-Hospital

🇩🇪

Hagen, Germany

Klinikum Kempten-Oberallgäu

🇩🇪

Kempten, Germany

Klinikum Leverkusen GmbH

🇩🇪

Leverkusen, Germany

Universitätsklinik Mainz

🇩🇪

Mainz, Germany

St. Clemens Hospital

🇩🇪

Oberhausen, Germany

University Clinic Großhadern

🇩🇪

München, Germany

Diakonie - Klinikum Stuttgart

🇩🇪

Stuttgart, Germany

Caritas Klinik St. Theresia

🇩🇪

Saarbrücken, Germany

Kreiskrankenhaus Schotten

🇩🇪

Schotten, Germany

St.-Marien-Krankenhaus

🇩🇪

Siegen, Germany

Städtisches Krankenhaus Villingen

🇩🇪

Villingen-Schwenningen, Germany

Asklepios Nordseeklinik

🇩🇪

Westerland, Germany

Sophien- und Hufeland Klinikum

🇩🇪

Weimar, Germany

© Copyright 2025. All Rights Reserved by MedPath